Triple-Hit Lymphoma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

BCL2
BCL2 Fusion
BCL6
BCL6 Fusion
CD19 Expression
EBV Positive
Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive
MS4A1 Expression
MYC
MYC Fusion

Overview

NCI Definition: A rare B-cell non-Hodgkin lymphoma that is characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and/ or BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis. [1]

Clinical Trials

View Clinical Trials for Triple-Hit Lymphoma

There are 30 clinical trials for triple-hit lymphoma, of which 26 are open and 4 are completed or closed. Of the trials that contain triple-hit lymphoma as an inclusion criterion, 1 is early phase 1 (1 open), 10 are phase 1 (9 open), 4 are phase 1/phase 2 (3 open), 10 are phase 2 (9 open), 3 are phase 2/phase 3 (2 open), and 2 are phase 3 (2 open).

BCL2, BCL6, and MYC are the most frequent gene inclusion criteria for triple-hit lymphoma clinical trials [3].

Trials Investigating Triple-Hit Lymphoma by Gene and Recruiting Status

Cyclophosphamide, rituximab, and fludarabine are the most common interventions in triple-hit lymphoma clinical trials.

Drugs Being Investigated in Triple-Hit Lymphoma Trials by Recruiting Status

Significant Genes in Triple-Hit Lymphoma

AFF1 +

AFF1 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK +

ALK is an inclusion eligibility criterion in 4 clinical trials for triple-hit lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

BCL2 +

BCL2 is an inclusion eligibility criterion in 30 clinical trials for triple-hit lymphoma, of which 26 are open and 4 are closed. Of the trials that contain BCL2 status and triple-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (9 open), 4 are phase 1/phase 2 (3 open), 10 are phase 2 (9 open), 3 are phase 2/phase 3 (2 open), and 2 are phase 3 (2 open) [3].

BCL6 +

BCL6 is an inclusion eligibility criterion in 30 clinical trials for triple-hit lymphoma, of which 26 are open and 4 are closed. Of the trials that contain BCL6 status and triple-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (9 open), 4 are phase 1/phase 2 (3 open), 10 are phase 2 (9 open), 3 are phase 2/phase 3 (2 open), and 2 are phase 3 (2 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IGH +

IGH is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IRF4 +

IRF4 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAF +

MAF is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAF status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAFB +

MAFB is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MAFB status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 30 clinical trials for triple-hit lymphoma, of which 26 are open and 4 are closed. Of the trials that contain MYC status and triple-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (9 open), 4 are phase 1/phase 2 (3 open), 10 are phase 2 (9 open), 3 are phase 2/phase 3 (2 open), and 2 are phase 3 (2 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and triple-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

WHSC1 +

WHSC1 is an inclusion eligibility criterion in 1 clinical trial for triple-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WHSC1 status and triple-hit lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

Disease Details

Synonyms

High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Triple Hit Lymphoma

Parent(s)

High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.